PDF(Pubmed)
Abstract：
Dentin hypersensitivity (DH) pain is a persistent clinical problem, which is a common condition known to affect patients\' quality of life (QoL), but no treatment has ever been agreed upon. Calcium phosphates, available in different forms, have properties that allow sealing the dentinal tubules, which may relieve dentin hypersensitivity. The aim of this systematic review is to evaluate the ability of different formulations of calcium phosphate to reduce dentin hypersensitivity pain level in clinical studies. The inclusion criterion was as follows: clinical randomized controlled studies using calcium phosphates in treating dentin hypersensitivity. In December 2022, three electronic databases (Pubmed, Cochrane and Embase) were searched. The search strategy was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The bias assessment risks results were carried out using the Cochrane Collaboration tool. A total of 20 articles were included and analyzed in this systematic review. The results show that calcium phosphates have properties that reduce DH-associated pain. Data compilation showed a statistically significant difference in DH pain level between T0 and 4 weeks. This VAS level reduction is estimated at about -2.5 compared to the initial level. The biomimetic and non-toxic characteristics of these materials make them a major asset in treating dentin hypersensitivity.
摘要：
牙本质过敏（DH）疼痛是一个持续的临床问题，这是一种常见的疾病，已知会影响患者的生活质量(QoL)，但从未就治疗达成一致.磷酸钙,以不同的形式提供，具有密封牙本质小管的特性，可以缓解牙本质过敏.这项系统评价的目的是评估临床研究中不同配方的磷酸钙降低牙本质过敏性疼痛水平的能力。纳入标准如下：使用磷酸钙治疗牙本质过敏的临床随机对照研究。2022年12月，三个电子数据库(Pubmed，搜索了Cochrane和Embase）。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目进行搜索策略。偏差评估风险结果是使用Cochrane协作工具进行的。本系统综述共纳入20篇文献并进行分析。结果显示磷酸钙具有减少DH相关疼痛的性质。数据汇编显示在T0和4周之间的DH疼痛水平具有统计学上的显著差异。与初始水平相比,该VAS水平降低估计为约-2.5。这些材料的仿生和无毒特性使其成为治疗牙本质过敏的主要资产。
